Evaluation of the Involvement of Heme Oxygenase-1 Expression in Discoid Lupus Erythematosus Lesions

Discoid lupus erythematosus (DLE) is a chronic autoimmune disease that primarily affects the skin, causing red, scaly patches that may be disfiguring and can cause permanent scarring. This study aimed to investigate the potential clinical and therapeutic applications of heme oxygenase-1 (HMOX1) in the context of DLE. Immunohistochemical staining and bioinformatics analysis were performed on skin biopsy samples from DLE patients to examine the levels of HMOX1 and to correlate with markers of inflammation. Our study revealed a negative correlation between HMOX1 levels and the inflammatory status of DLE lesions, as well as an inverse correlation between HMOX1 levels and the infiltration of M1 macrophages and activated mastocytes. These findings suggest that HMOX1 plays a crucial role in the regulation of inflammation in DLE and could be a potential therapeutic target and biomarker for DLE.

[1]  L. Eckhart,et al.  Heme Oxygenase-1 Is Upregulated during Differentiation of Keratinocytes but Its Expression Is Dispensable for Cornification of Murine Epidermis , 2023, Journal of developmental biology.

[2]  M. Maz,et al.  Recent advances in cutaneous lupus. , 2022, Journal of autoimmunity.

[3]  A. Cuadrado,et al.  Protective actions of nuclear factor erythroid 2-related factor 2 (NRF2) and downstream pathways against environmental stressors. , 2022, Free radical biology & medicine.

[4]  L. Tsoi,et al.  B Cell Signatures Distinguish Cutaneous Lupus Erythematosus Subtypes and the Presence of Systemic Disease Activity , 2021, Frontiers in Immunology.

[5]  V. Bhandari,et al.  A structurally preserved allosteric site in the MIF superfamily affects enzymatic activity and CD74 activation in D-dopachrome tautomerase , 2021, The Journal of biological chemistry.

[6]  E. Cavalli,et al.  Macrophage Migration Inhibitory Factor (MIF) and Its Homologue D-Dopachrome Tautomerase (DDT) Inversely Correlate with Inflammation in Discoid Lupus Erythematosus , 2021, Molecules.

[7]  R. Bucala,et al.  The immunobiology of MIF: function, genetics and prospects for precision medicine , 2019, Nature Reviews Rheumatology.

[8]  P. Boor,et al.  Evolving complexity of MIF signaling. , 2019, Cellular signalling.

[9]  J. Hodgin,et al.  The female-biased factor VGLL3 drives cutaneous and systemic autoimmunity. , 2019, JCI insight.

[10]  Alireza Hadj Khodabakhshi,et al.  Metascape provides a biologist-oriented resource for the analysis of systems-level datasets , 2019, Nature Communications.

[11]  Matthew T. Patrick,et al.  Hypersensitive IFN Responses in Lupus Keratinocytes Reveal Key Mechanistic Determinants in Cutaneous Lupus , 2019, The Journal of Immunology.

[12]  P. Fagone,et al.  Role of MIF and D-DT in immune-inflammatory, autoimmune, and chronic respiratory diseases: from pathogenic factors to therapeutic targets. , 2019, Drug discovery today.

[13]  F. Lacarrubba,et al.  Discoid lupus erythematosus: Reflectance confocal microscopy features correlate with horizontal histopathological sections , 2018, Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging.

[14]  E. Mazzon,et al.  Gasotransmitters and the immune system: Mode of action and novel therapeutic targets , 2018, European journal of pharmacology.

[15]  James T. Elder,et al.  Photosensitivity and type I IFN responses in cutaneous lupus are driven by epidermal-derived interferon kappa , 2018, Annals of the rheumatic diseases.

[16]  S. Mammana,et al.  Involvement of the Nrf2/HO‐1/CO axis and therapeutic intervention with the CO‐releasing molecule CORM‐A1, in a murine model of autoimmune hepatitis , 2018, Journal of cellular physiology.

[17]  D. Bourdette,et al.  MIF and D-DT are potential disease severity modifiers in male MS subjects , 2017, Proceedings of the National Academy of Sciences.

[18]  C. Berthier,et al.  Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon–Induced Up‐Regulation of Interferon Regulatory Factor 1 , 2017, Arthritis & rheumatology.

[19]  S. Aiba,et al.  Epidermal iron metabolism for iron salvage. , 2017, Journal of dermatological science.

[20]  Angela N. Brooks,et al.  A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles , 2017, Cell.

[21]  D. Liggitt,et al.  Ultraviolet B Irradiation Causes Stimulator of Interferon Genes–Dependent Production of Protective Type I Interferon in Mouse Skin by Recruited Inflammatory Monocytes , 2017, Arthritis & rheumatology.

[22]  Dexter Hadley,et al.  Systematic integration of biomedical knowledge prioritizes drugs for repurposing , 2017, bioRxiv.

[23]  C. Orteu,et al.  Severe recalcitrant cutaneous manifestations in systemic lupus erythematosus successfully treated with fumaric acid esters , 2017, The British journal of dermatology.

[24]  Shangha Pan,et al.  CORM-2 inhibits TXNIP/NLRP3 inflammasome pathway in LPS-induced acute lung injury , 2016, Inflammation Research.

[25]  Bingrong Liu,et al.  The therapeutic effect of CORM-3 on acute liver failure induced by lipopolysaccharide/D-galactosamine in mice. , 2016, Hepatobiliary & pancreatic diseases international : HBPD INT.

[26]  S. Mammana,et al.  Carbon monoxide-releasing molecule-A1 (CORM-A1) improves clinical signs of experimental autoimmune uveoretinitis (EAU) in rats. , 2015, Clinical immunology.

[27]  R. Bomprezzi.  Dimethyl fumarate in the treatment of relapsing–remitting multiple sclerosis: an overview , 2015, Therapeutic advances in neurological disorders.

[28]  T. Luger,et al.  Successful treatment of discoid lupus erythematosus with fumaric acid esters. , 2014, Journal of the American Academy of Dermatology.

[29]  R. Foresti,et al.  Heme oxygenase-1 as a target for drug discovery. , 2014, Antioxidants & redox signaling.

[30]  F. Nicoletti,et al.  Pharmacological application of carbon monoxide ameliorates islet-directed autoimmunity in mice via anti-inflammatory and anti-apoptotic effects , 2014, Diabetologia.

[31]  A. Kuhn,et al.  The classification and diagnosis of cutaneous lupus erythematosus. , 2014, Journal of autoimmunity.

[32]  S. Mammana,et al.  Heme oxygenase-1 expression in peripheral blood mononuclear cells correlates with disease activity in multiple sclerosis , 2013, Journal of Neuroimmunology.

[33]  R. Bucala,et al.  D-dopachrome tautomerase (D-DT or MIF-2): doubling the MIF cytokine family. , 2012, Cytokine.

[34]  M. Alcaraz,et al.  Downregulation of the Inflammatory Response by CORM-3 Results in Protective Effects in a Model of Postmenopausal Arthritis , 2012, Calcified Tissue International.

[35]  P. Fagone,et al.  Therapeutic potential of carbon monoxide in multiple sclerosis , 2012, Clinical and experimental immunology.

[36]  P. Fagone,et al.  Prevention of clinical and histological signs of proteolipid protein (PLP)‐induced experimental allergic encephalomyelitis (EAE) in mice by the water‐soluble carbon monoxide‐releasing molecule (CORM)‐A1 , 2011, Clinical and experimental immunology.

[37]  J. Bernhagen,et al.  MIF: a key player in cutaneous biology and wound healing , 2011, Experimental dermatology.

[38]  L. Otterbein,et al.  The therapeutic potential of carbon monoxide , 2010, Nature Reviews Drug Discovery.

[39]  M. Alcaraz,et al.  The CO-releasing molecule CORM-3 protects against articular degradation in the K/BxN serum transfer arthritis model. , 2010, European journal of pharmacology.

[40]  B. Croker,et al.  Sunlight Triggers Cutaneous Lupus through a CSF-1-Dependent Mechanism in MRL-Faslpr Mice 1 , 2008, The Journal of Immunology.

[41]  J. Bernhagen,et al.  MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment , 2007, Nature Medicine.

[42]  M. Hickey,et al.  Macrophage Migration Inhibitory Factor Deficiency Attenuates Macrophage Recruitment, Glomerulonephritis, and Lethality in MRL/lpr Mice1 , 2006, The Journal of Immunology.

[43]  J. Bernhagen,et al.  MIF: a new cytokine link between rheumatoid arthritis and atherosclerosis , 2006, Nature Reviews Drug Discovery.

[44]  R. Foresti,et al.  Therapeutic applications of carbon monoxide-releasing molecules , 2005, Expert opinion on investigational drugs.

[45]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[46]  R. Alberto,et al.  CORM‐A1: a new pharmacologically active carbon monoxide‐releasing molecule , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[47]  Jiang Li,et al.  Genetic dissection of systemic autoimmune disease in Nrf2-deficient mice. , 2004, Physiological genomics.

[48]  R. Foresti,et al.  Bioactivity and pharmacological actions of carbon monoxide-releasing molecules. , 2003, Current pharmaceutical design.

[49]  Gary D. Bader,et al.  An automated method for finding molecular complexes in large protein interaction networks , 2003, BMC Bioinformatics.

[50]  J. Bernhagen,et al.  Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1 , 2000, Nature.

[51]  B. Rollins,et al.  Monocyte Chemoattractant Protein 1–Dependent Leukocytic Infiltrates Are Responsible for Autoimmune Disease in Mrl-Faslpr Mice , 1999, The Journal of experimental medicine.

[52]  K. Okumura,et al.  Expression of Fas ligand and its receptor in cutaneous lupus: implication in tissue injury. , 1997, Clinical immunology and immunopathology.

[53]  Ash A. Alizadeh,et al.  Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx. , 2020, Methods in molecular biology.

[54]  F. Nicoletti,et al.  MIF in autoimmunity and novel therapeutic approaches. , 2009, Autoimmunity reviews.